

Claims

1. Use of an anti-CD19 antibody in the manufacture of a medicament for the treatment of primary refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide, wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
2. Use of lenalidomide in the manufacture of a medicament for the treatment of primary refractory DLBCL in combination with an anti-CD19 antibody, wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO:6).
3. Use of an anti-CD19 antibody in the manufacture of a medicament for the treatment of non-germinal center B-cell type (non-GCB) DLBCL in combination with lenalidomide, wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO:6).
4. Use of lenalidomide in the manufacture of a medicament for the treatment of non-germinal center B-cell type (non-GCB) DLBCL in combination with an anti-CD19 antibody, wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO:6).

5. The use of claim 3, wherein the non-GCB DLBCL is non-GCB relapsed or refractory DLBCL.
6. The use of claim 4, wherein the non-GCB DLBCL is non-GCB relapsed or refractory DLBCL.
7. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody comprises a variable heavy chain comprising the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
KYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQTL
VTVSS (SEQ ID NO: 7)
and a variable light chain comprising the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTSSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID
NO: 8).
8. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody comprises a heavy chain comprising the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
KYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQTL
VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPP
AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP
APPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAK
TKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSDGSF
FLYSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11)
and a light chain comprising the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTSSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12).
9. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody and lenalidomide are formulated in different pharmaceutical compositions.

10. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody is formulated in a pharmaceutical composition for intravenous administration and lenalidomide is formulated in a pharmaceutical composition for oral administration.
11. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody and lenalidomide are to be administered in separate compositions.
12. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody and lenalidomide are to be administered on the same day.
13. The use of any one of claims 1 to 6, wherein the anti-CD19 antibody and lenalidomide are to be administered on different days.